Cost–effectiveness of the prophylactic HPV vaccine: An application to the Netherlands taking non-cervical cancers and cross-protection into account
Highlights • We examine the cost–effectiveness of the bivalent HPV-vaccine. • Cross-protection and protection against non-cervical cancers are taken into account. • The cost–effectiveness ratio (CER) was €5815 per quality adjusted life year. • The CER falls far below the Dutch willingness-to-pay thr...
Saved in:
Published in | Vaccine Vol. 31; no. 37; pp. 3922 - 3927 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Kidlington
Elsevier Ltd
20.08.2013
Elsevier Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Highlights • We examine the cost–effectiveness of the bivalent HPV-vaccine. • Cross-protection and protection against non-cervical cancers are taken into account. • The cost–effectiveness ratio (CER) was €5815 per quality adjusted life year. • The CER falls far below the Dutch willingness-to-pay threshold of €20,000/QALY. • The CER is sensitive to vaccine price, cost and disutility of cervical cancer. |
---|---|
Bibliography: | http://dx.doi.org/10.1016/j.vaccine.2013.06.044 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
ISSN: | 0264-410X 1873-2518 |
DOI: | 10.1016/j.vaccine.2013.06.044 |